[ Teewinot Life Sciences raises $12.3M in Series B ]
Teewinot Life Sciences has raised $12.3 million in Series B funding.
Founded in 2015, Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology.
The capital raised will be used for a variety of activities including enhancement and acceleration of research and development activities, expanding business development opportunities, and adding to the existing patent portfolio.
|Founder / CEO||Jeffrey M. Korentur|
|Previous Investors||same as above|